9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
NA ElSayed, G Aleppo, VR Aroda, RR Bannuru… - Diabetes …, 2023 - Am Diabetes Assoc
The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …
ADA's current clinical practice recommendations and is intended to provide the components …
6. Glycemic Targets: Standards of Care in Diabetes—2023
NA ElSayed, G Aleppo, VR Aroda, RR Bannuru… - Diabetes …, 2023 - Am Diabetes Assoc
The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …
ADA's current clinical practice recommendations and is intended to provide the components …
5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes—2023
NA ElSayed, G Aleppo, VR Aroda, RR Bannuru… - Diabetes …, 2023 - Am Diabetes Assoc
The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …
ADA's current clinical practice recommendations and is intended to provide the components …
Oxidative stress in the pathophysiology of type 2 diabetes and related complications: Current therapeutics strategies and future perspectives
JS Bhatti, A Sehrawat, J Mishra, IS Sidhu… - Free Radical Biology …, 2022 - Elsevier
Abstract Type 2 diabetes (T2DM) is a persistent metabolic disorder rising rapidly worldwide.
It is characterized by pancreatic insulin resistance and β-cell dysfunction. Hyperglycemia …
It is characterized by pancreatic insulin resistance and β-cell dysfunction. Hyperglycemia …
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the …
A Gastaldelli, K Cusi, LF Landó, R Bray… - The lancet Diabetes & …, 2022 - thelancet.com
Background Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP)
and glucagon-like peptide-1 receptor agonist under development for the treatment of type 2 …
and glucagon-like peptide-1 receptor agonist under development for the treatment of type 2 …
[HTML][HTML] Glycemia reduction in type 2 diabetes—glycemic outcomes
GRADE Study Research Group - New England Journal of …, 2022 - Mass Medical Soc
Background The comparative effectiveness of glucose-lowering medications for use with
metformin to maintain target glycated hemoglobin levels in persons with type 2 diabetes is …
metformin to maintain target glycated hemoglobin levels in persons with type 2 diabetes is …
American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan—2022 update
L Blonde, GE Umpierrez, SS Reddy, JB McGill… - Endocrine Practice, 2022 - Elsevier
Objective The objective of this clinical practice guideline is to provide updated and new
evidence-based recommendations for the comprehensive care of persons with diabetes …
evidence-based recommendations for the comprehensive care of persons with diabetes …
[HTML][HTML] Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments
R Ruze, T Liu, X Zou, J Song, Y Chen, R Xu… - Frontiers in …, 2023 - frontiersin.org
The prevalence of obesity and diabetes mellitus (DM) has been consistently increasing
worldwide. Sharing powerful genetic and environmental features in their pathogenesis …
worldwide. Sharing powerful genetic and environmental features in their pathogenesis …
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised …
Background GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE)
in patients with type 2 diabetes. However, uncertainty regarding kidney outcomes persists …
in patients with type 2 diabetes. However, uncertainty regarding kidney outcomes persists …
[HTML][HTML] Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management
CX Ma, XN Ma, CH Guan, YD Li, D Mauricio… - Cardiovascular …, 2022 - Springer
Cardiovascular diseases (CVDs) are the main cause of death among patients with type 2
diabetes mellitus (T2DM), particularly in low-and middle-income countries. To effectively …
diabetes mellitus (T2DM), particularly in low-and middle-income countries. To effectively …